)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
bluebird bio
bluebird bio (BLUE) investor relations material
bluebird bio has been delisted
bluebird bio Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary14 May, 2025
Executive summary
Entered into a Merger Agreement with Beacon Parent Holdings, L.P.; tender offer commenced for all outstanding shares, with closing expected in the first half of 2025.
Focused on commercializing three FDA-approved gene therapies: ZYNTEGLO, SKYSONA, and LYFGENIA, with all product revenue in the U.S.
Significant financial and operational risks if the Merger Transaction does not close, including risk of bankruptcy due to loan default.
Financial highlights
Q1 2025 net product revenue was $38.7M, up from $18.6M in Q1 2024, driven by eight additional infusions.
Net loss for Q1 2025 was $29.1M, a significant improvement from $69.8M in Q1 2024.
Gross margin improved to $26.5M from a negative $7.3M year-over-year.
Cash and cash equivalents as of March 31, 2025 were $78.7M; accumulated deficit reached $4.5B.
Operating expenses decreased to $51.1M from $71.4M year-over-year, reflecting lower SG&A and R&D costs.
Outlook and guidance
Existing cash and equivalents expected to fund operations into June 2025 and through anticipated Merger closing, assuming continued cost-saving and vendor payment deferrals.
If the Merger does not close by June 20, 2025, immediate loan default and risk of bankruptcy are anticipated.
No new clinical trials planned in Europe; U.S. commercialization remains the focus.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from bluebird bio
- Restructuring aims for 20% cost cuts and breakeven in H2 2025, driven by patient start growth.BLUE
Status Update - Q3 revenue was $10.6M; patient starts and cash flow outlook improved, but funding risks persist.BLUEQ3 2024
- Gene therapy launches accelerate as payer coverage grows, but new funding is needed soon.BLUE2024 Wells Fargo Healthcare Conference
- Gene therapy launches accelerate with strong demand, broad access, and a path to profitability.BLUEMorgan Stanley 22nd Annual Global Healthcare Conference
- Q2 revenue up to $16.1M, strong demand, but losses widen and funding uncertainty persists.BLUEQ2 2024
- FY 2024 revenue rose 184% to $83.8M, but liquidity risks persist amid a pending merger.BLUEQ4 2024
bluebird bio
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company's product portfolio comprises two clinical-stage lentiviral-based gene therapy product candidates for the treatment of transfusion-dependent b-thalassemia (TDT) and severe sickle cell disease (SCD); and a preclinical-stage gene therapy product candidate for the treatment of childhood cerebral adrenoleukodystrophy. Its clinical development programs include LentiGlobin BB305 program to treat TDT and SCD; and Lenti-D that is in Phase II/III trial to treat cerebral adrenoleukodystrophy. The company has collaboration agreements with Celgene Corporation; Intellia Therapeutics, Inc.; Catalent Biologics LLC; Kite Pharma, Inc.; Genethon S.A.; and University of Pennsylvania. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts